Navigation Links
Dangerous experiment in fetal engineering
Date:8/3/2012

CHICAGO --- A new paper just published in the Journal of Bioethical Inquiry uses extensive Freedom of Information Act findings to detail an extremely troubling off-label medical intervention employed in the U.S. on pregnant women to intentionally engineer the development of their fetuses for sex normalization purposes.

The paper is authored by Alice Dreger, professor of clinical medical humanities and bioethics at Northwestern University Feinberg School of Medicine and is co-authored by Ellen Feder, associate professor of philosophy and religion at American University, and Anne Tamar-Mattis, executive director of Advocates for Informed Choice.

The pregnant women targeted are at risk for having a child born with the condition congenital adrenal hyperplasia (CAH), an endocrinological condition that can result in female fetuses being born with intersex or more male-typical genitals and brains. Women genetically identified as being at risk are given dexamethasone, a synthetic steroid, off-label starting as early as week five of the first trimester to try to "normalize" the development of those fetuses, which are female and CAH-affected. Because the drug must be administered before doctors can know if the fetus is female or CAH-affected, only one in eight of those exposed are the target type of fetus.

The off-label intervention does not prevent CAH; it aims only at sex normalization. Like Diethylstilbestrol (DES) -- which is now known to have caused major fertility problems and fatal cancers among those exposed in utero -- dexamethasone is a synthetic steroid. Dexamethasone is known -- and in this case intended -- to cross the placental barrier and change fetal development. Experts estimate the glucocorticoid dose reaching the fetus is 60 to 100 times what the body would normally experience.

The new report provides clear evidence that:

  • For more than 10 years, medical societies repeatedly but ultimately impotently expressed high alarm at use of this off-label intervention outside prospective clinical trials, because it is so high risk and because nearly 90 percent of those exposed cannot benefit.

  • Mothers offered the intervention have been told it "has been found safe for mother and child" but in fact there has never been any such scientific evidence.

  • The U.S. Food and Drug Administration has indicated it cannot stop advertising of this off-label use as "safe for mother and child" because the advertising is done by a clinician not affiliated with the drug maker.

  • A just-out report from Sweden in the Journal of Clinical Endocrinology and Metabolism documents a nearly 20 percent "serious adverse event" rate among the children exposed in utero.

  • Clinician proponents of the intervention have been interested in whether the intervention can reduce rates of tomboyism, lesbianism and bisexuality, characteristics they have termed "behavioral masculinization."

  • The National Institutes of Health has funded research to see if these attempts to prevent "behavioral masculinization" with prenatal dexamethasone are "successful."

  • The United States' systems designed to prevent another tragedy like DES and thalidomide -- involving de facto experimentation on pregnant women and their fetuses -- appear to be broken and ineffectual.


'/>"/>
Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. Dangerous caregivers for elderly
2. Dangerous Rage May Be Common Among U.S. Teens
3. New iTeen365 White Paper Identifies Dangerous Driving Distractions – Offers Solutions for Parents of Teen Drivers
4. U.S. Blood Supply at Dangerously Low Levels: Red Cross
5. Blood test for pregnant women could predict risk of having dangerously small babies
6. Prenatal exposure to pollution especially dangerous for children with asthma
7. Young Risk-Takers Drawn to Dangerous Choking Game
8. Experimental Drug Suppresses Appetite in Mice: Study
9. Experimental Chemical Helps Blind Mice See
10. Experimental drug may extend therapeutic window for stroke
11. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , M.D., ... Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . Dr. ... Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., who ...
(Date:7/24/2017)... ... July 24, 2017 , ... Cosmetic Town, an online plastic surgery information ... they perform on a daily basis. , The new video series will feature ... in at their practices. , When asked about the new video series, the ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... partnered together for a unique opportunity that helps high school girls succeed in ... Barriers, Creating Opportunities.” Horizon Goodwill will host over 20 high school girls ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... scholarship awards to be awarded annually to and divided between two full-time university ... bringing awareness to Amazonian plant medicine. To apply for the scholarship, students are ...
(Date:7/24/2017)... ... , ... Every year, thousands of dedicated Higher Education and K12 professionals flock ... coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to take ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs secured ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment ... in 2021, according to Medical Equipment & ... by Freedonia Focus Reports. Continued increases in demand for ... aging of the population and supported by gains in ... equipment and supplies. New product introductions will also drive ...
(Date:7/10/2017)... N.C. , July 10, 2017 Locus ... Convertible Note to support the development of CRISPR-Cas3 antimicrobial ... Holdings Limited, a leading Chinese Internet services provider, and ... will advance multiple infectious disease product programs targeting antibiotic ... Founded by Dr. Rodolphe Barrangou ...
Breaking Medicine Technology: